Belkyra Double Chin Plan: Sessions and Spacing

What Health Canada Recommends, And How To Plan

“How many sessions will I need?” is usually the first planning question I hear from clients across Toronto, Vaughan, and the GTA who are considering BELKYRA for under chin fullness.

Health Canada’s product monograph is clear on the structure of treatment: “Up to 6 treatments spaced at intervals of no less than 1 month apart are recommended based on the clinical trial efficacy and safety data.” It also states that the number of sessions needed for a satisfactory response depends on the individual patient.

Spacing matters for a second reason that affects real life scheduling: in the monograph trial data, swelling is very common, reported as “edema/swelling” in 87% of BELKYRA treated subjects. Planning your series means planning your calendar.

How Many Belkyra Sessions Are Typical

Session planning starts with the only schedule Health Canada specifically ties to evaluated safety and efficacy data. The BELKYRA product monograph states that the number of treatment sessions needed to achieve a satisfactory response depends on the individual patient.

It also sets the outer limits and the spacing rule: “Up to 6 treatments spaced at intervals of no less than 1 month apart are recommended based on the clinical trial efficacy and safety data.” In the same document, Health Canada advises: “Patients should receive the minimum number of injections over a minimum number of treatment sessions to achieve a satisfactory result.”

Why You Will See at Least One Month Apart Everywhere

The monograph links spacing directly to what has been studied. More frequent dosing has a specific caution: “More frequent dosing with BELKYRA has not been clinically evaluated for safety and effectiveness and is not recommended.” For you, this is primarily a planning point. If you are aiming for a certain season or event, the evidence based approach means building enough time between sessions.

What the Research Adds, Without Changing the Canadian Schedule

A phase III randomized, double blind, placebo controlled study of ATX 101 in moderate to severe submental fat (n=363) used up to four treatment sessions approximately 28 days apart, with a 12 week follow up. In that study, reductions were reported as more pronounced after the first two or three treatments, but continued throughout the treatment period.

The same study also observed that some ATX 101 recipients required fewer than four treatment sessions due to early therapeutic success (reported as 7.5% and 10.7%, respectively). These are study observations, not a different recommended Canadian dosing schedule, and your plan still needs to respect Health Canada’s “no less than 1 month” spacing.

What Belkyra Targets Under the Chin

People use “double chin” as a catch all phrase, but BELKYRA is authorized for a specific target. Health Canada states: “BELKYRA deoxycholic acid injection is indicated for: Improvement in the appearance of moderate to severe convexity or fullness associated with submental fat (SMF) in adults.”

This is also why a careful assessment matters more than a generic appointment. If the fullness you see is not driven by submental fat, the right plan may be a different plan.

The Plane Matters, and It Is in the Label

The product monograph is explicit about where the medication is intended to go: “BELKYRA should be administered into preplatysmal subcutaneous fat tissue and not into postplatysmal fat.” It also instructs clinicians to identify subcutaneous fat between the dermis and platysma (pre platysmal fat) and to avoid injecting into post platysmal fat.

From a client perspective, this matters because session planning and spacing only make sense when the concern matches the target, and the injector is working with the correct anatomy.

On Label Boundaries to Know Before You Plan

Health Canada lists two important limitations of use. First: “The safe and effective use of BELKYRA for use outside the submental region has not been established and is not recommended.” Second: “The safe and effective use of BELKYRA for use in patients with mild or extreme SMF has not been established and is not recommended.”

If your under chin fullness is mild, or if it is at the other end of the spectrum, the useful next step is not booking a series, it is an assessment of what is actually creating the look you want to change. On our side, this is the kind of conversation that sits well inside a Facial harmonization mindset, because the best plan is driven by structure and proportion, not by a single trend.

Spacing Your Appointments Around Swelling and Visibility

Belkyra session spacing is not only about rules on paper. It is also about how you need to look and feel in your day to day life after each visit.

In the Health Canada monograph’s adverse reaction table (reported in at least 2% of subjects), local effects are common. BELKYRA subjects reported “edema/swelling” in 87% and “hematoma/bruising” in 72%. Other reported reactions in the table include pain (70%), numbness (66%), erythema (27%), induration (23%), paresthesia (14%), nodule (13%), pruritus (12%), and skin tightness (5%).

One Non Obvious Planning Trade Off

Spacing is often discussed as “why you have to wait.” The more practical issue is that each session can bring a visible recovery window, and the treatment series can extend across multiple months because Health Canada recommends intervals of no less than 1 month apart, for up to 6 treatments. If you have work travel, professional photos, weddings, or a stretch of presentations, you may prefer to start earlier and build your series around the months where swelling and bruising are less disruptive.

If you want a preview of how our clinic generally approaches planning for swelling and bruising across injectable treatments, the guidance on Patient information and care is a good place to start reading before a consultation.

Consult Checklist Before You Commit to a Series

A good Belkyra plan begins by confirming you are treating submental fat, within the product’s authorized use, and that there is no other medical reason for fullness under the chin.

Screening for Other Causes of Under Chin Fullness

The BELKYRA product monograph states: “Patients should be screened for other potential causes of submental convexity/fullness (e.g., thyromegaly and cervical lymphadenopathy) prior to use of BELKYRA.” It also states: “Thyroid disease/conditions should be ruled out prior to use as a potential contributing cause of submental convexity/fullness (i.e., thyromegaly).”

Questions That Change the Plan

These are the kinds of points worth raising early, because they affect whether treatment is appropriate and how you schedule it:

• Is there any sign of infection in the treatment area? Health Canada lists “the presence of infection in the treatment area” as a contraindication for BELKYRA.
• Do you have bleeding abnormalities, or are you currently treated with antiplatelet or anticoagulant therapy? The monograph states BELKYRA should be used with caution in these patients.
• Do you have a history of dysphagia? The monograph states dysphagia occurred in 2% of BELKYRA treated patients in clinical trials, with duration ranging from 1 to 81 days (median 3 days), and that BELKYRA is not recommended for patients with a history of dysphagia.
• Do you have excessive skin laxity or prominent platysmal bands? The monograph states BELKYRA should not be used in patients with excessive skin laxity, prominent platysmal bands, or other conditions for which reduction of submental fat may result in an aesthetically undesirable outcome.

Choosing a Qualified Injector for This Area

Health Canada emphasizes anatomy knowledge and prior procedure history in the submental region. The monograph states the health care professional should understand relevant submental anatomy and associated neuromuscular and vascular structures, including any alterations related to prior surgical or aesthetic procedures. If you are reading this while choosing a provider, this is a reasonable standard to ask about directly. You can also read more about who performs treatments at Aesthetic Nurse Marta on the About Marta morozova page.

Why the Injection Plan Is Part of Your Decision

Even though your consultation will be personalized, it can help to know that the product monograph includes specifics about how BELKYRA is administered. These are clinical details your injector plans for, and they connect to safety.

Health Canada describes dosing and spacing, including: “Inject 0.2 mL in each site, 1 cm apart, up to 50 injections into the subcutaneous fat,” and “The maximum dose should not exceed 100 mg (10 mL) in a single treatment.” It also includes placement requirements such as inserting the needle perpendicular to the skin until it is mid point into the underlying preplatysmal subcutaneous fat layer, and location warnings including: “Do not inject above the inferior border of the mandible.”

A planning point that many people do not consider until they hear it: BELKYRA is supplied as “deoxycholic acid injection 10 mg/mL solution” in “2 mL, single use vials.” A series is not one event, it is a structured course of care, and your comfort with the plan, the spacing, and the recovery pattern should be part of the decision.

If you are considering Belkyra, treat your timeline as part of the treatment. Health Canada recommends up to 6 treatments, spaced no less than 1 month apart, and swelling is common in the trial data, so your calendar matters.

If you would like an anatomy first assessment for under chin fullness, you can start with our fat dissolving injections page, then request a consultation to plan session spacing around your work and social schedule.